Forum Topic

Time to Postpone Trade Talks with the EU?

It perplexes me that more people are not raising the obvious question of why we are intending to persist with reshaping our relationship with the EU, a path which will involve a huge amount of dislocation for our economy when the coronavirus is already causing this to happen. This doesn't mean rejoining the EU but postponing the trade talks and remaining aligned with the single market until we are clear of the current crisis. The massive demands that the talks will place on an already overstretched civil service are bound to create a range of difficulties.Our PM is not known for his work ethic but even a more conscientous leader would struggle to cope with the workload that will be placed on them.If we leave the EU during a pandemic we reduce the ability of our universities to work with other institutions in Europe to develop a cure.It has already been reported that outside EU institutions we will not have the same access to EU developed vaccines that hopefully will become available.We have over the past few days had ample demonstration how even minor disruptions to supply chains can lead to hoarding and shortages. If the pandemic is still an issue and any new trading arrangement interrupt the free low of goods, there will be far worse scenes in our local shops and many people will have to go without basic essentials.The notion that freedom of movement presents an extra risk during a pandemic has been thoroughly disproven with EU countries closing their borders to each other for health reasons.If you don't agree that trade talks should be put on hold could you explain to me what are the benefits which outweigh all the negatives detailed above?

Mark Evans ● 2059d27 Comments

Sir Patrick VallanceGovernment Chief Scientific Adviser and Head of Government Science and Engineering ProfessionSir Patrick Vallance FRS FMedSci FRCP is Government Chief Scientific Adviser (GCSA) and Head of the Government Science and Engineering (GSE) profession. His personal research was in the area of diseases of blood vessels and endothelial biology.Patrick was President, R&D at GlaxoSmithKline (GSK) from 2012 until 2017. Prior to this, he was Senior Vice President, Medicines Discovery and Development. He joined the company in May 2006 as Head of Drug Discovery. He was a member of the GSK Board and the Corporate Executive Team. During his period as head of R&D over 14 new medicines were approved for use worldwide, for diseases ranging from cancer to asthma and HIV.Prior to joining GSK, he was a clinical academic, Professor of Medicine and led the Division of Medicine at UCL. He has over 20 years’ experience of basic and clinical research, and was a consultant physician in the NHS. His research spanned from work on medicinal chemistry and structural biology, through to cellular work, studies in humans and use of large electronic health record databases.He was elected to the Academy of Medical Sciences in 1999 and to the Royal Society in 2017. He was on the Board of the UK Office for Strategic Co-ordination of Health Research (OSCHR) from 2009 to 2016. He is an Honorary Fellow at UCL and holds honorary degrees from Imperial College London, Glasgow University, University of York and St George’s, University of London. He was a non-executive director and board member for UK Biobank and a non-executive board member for Genome Research Limited but stepped down in taking up the GCSA role.Government Chief Scientific AdviserThe Government Chief Scientific Adviser (GCSA) is responsible for:providing scientific advice to the Prime Minister and members of cabinetadvising the government on aspects of policy on science and technologyensuring and improving the quality and use of scientific evidence and advice in governmentGovernment Office for ScienceHead of Government Science and Engineering ProfessionThe Head of the Government Science and Engineering Profession is responsible for:leading the science and engineering profession within the Civil Serviceco-ordinating and encouraging the sharing of good practiceworking with departmental Heads of Science and Engineering Profession (HoSEPs) to ensure that scientists are able to access the right professional skills and learning and development activities within their departmentsGovernment Science & Engineering Professionhttps://www.gov.uk/government/people/patrick-vallance

Rosco White ● 2058d

Professor Chris Whitty ("......Chris is an epidemiologist and has undertaken research in the UK, Africa and Asia.)Chief Medical Officer & DHSC Chief Scientific AdviserProfessor Chris Whitty is Chief Medical Officer (CMO) for England, the UK government’s Chief Medical Adviser and head of the public health profession.Chris is also Chief Scientific Adviser for the Department of Health and Social Care (DHSC), with overall responsibility for the department’s research and development, including the National Institute for Health Research (NIHR).Chris is a practising NHS Consultant Physician at University College London Hospitals (UCLH) and the Hospital for Tropical Diseases, and Gresham Professor of Physic at Gresham College.[NOTE] :-Chris is an epidemiologist and has undertaken research in the UK, Africa and Asia. He was Professor of Public and International Health at the London School of Hygiene & Tropical Medicine (LSHTM) before becoming CMO.Previously Chris was the interim Government Chief Scientific Adviser 2017 to 2018 and, before that, the Chief Scientific Adviser at the Department for International Development (DFID).Chief Medical OfficerThe Chief Medical Officer (CMO) acts as the UK government’s principal medical adviser, and the professional head of all directors of public health in local government and the medical profession in government.The CMO provides public health and clinical advice to ministers in the Department of Health and Social Care (DHSC) and across government.The CMO is an independent position at permanent secretary level.https://www.gov.uk/government/people/christopher-whitty

Rosco White ● 2058d